Pulmatrix (NASDAQ:PULM – Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.66, FiscalAI reports.
Pulmatrix Price Performance
Shares of PULM stock traded up $0.04 during mid-day trading on Monday, hitting $1.33. The stock had a trading volume of 18,417 shares, compared to its average volume of 39,731. The firm has a market cap of $4.85 million, a PE ratio of -1.21 and a beta of 1.95. The company’s 50-day simple moving average is $1.46 and its 200-day simple moving average is $1.66. Pulmatrix has a fifty-two week low of $1.06 and a fifty-two week high of $4.98.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmatrix in a research note on Thursday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Get Our Latest Research Report on PULM
Pulmatrix Company Profile
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies. Its proprietary iSPERSE technology is designed to deliver dry-powder medicines to the lungs, and the company’s work has included treatments for respiratory diseases as well as medicines delivered through the lungs for other conditions. Among its drug candidates, PUR1900 is an inhaled formulation of itraconazole being developed for allergic bronchopulmonary aspergillosis, a lung condition associated with fungal sensitivity.
Featured Stories
- Five stocks we like better than Pulmatrix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
